xBiotech USA, Inc.

118 articles about xBiotech USA, Inc.

• XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

  10/23/2019

  XBiotech Inc. announced that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen weeks of therapy.

• Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients

  7/9/2019

  Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”

• XBiotech Announces Presentation of Data From Phase II Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

  1/26/2018

  The study achieved its primary endpoint, showing significant treatment benefit using the HiSCR endpoint.

• XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

  1/25/2018

  The 514G3 antibody was a naturally occurring antibody derived from a healthy individual with highly targeted immunity against S. aureus capable of neutralizing all strains of the bacteria, including a drug-resistant or so-called MRSA form.

• XBiotech Announces Presentation of Phase II Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

  1/19/2018

  The findings being presented come from patients that had received placebo in a previous Phase 2 double-blind, placebo-controlled study.

• XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology

  12/4/2017

  The publication highlights the efficacy of MABp1, in which the study’s primary endpoint was met in 60% of MABp1 treated patients compared to 10% of placebo patients.

• XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions

  11/14/2017

  IL-1a Neutralizing Antibody MABp1 Found to Block NETs’ Ability to Increase Endothelial Activation and Thrombogenicity

• XBiotech Announces First Patient in Study Evaluating MABp1 in Combination With Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

  10/18/2017

  The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator.

• XBiotech Announces Addition Of Renowned Dermatologist Dr. William Levis To Its Scientific Advisory Board

  10/3/2017

• XBiotech Announces Agreement With Cedars-Sinai Medical Center To Evaluate Mabp1 In Combination With Onivyde? And 5-Fluorouracil/Folinic Acid For The Treatment Of Pancreatic Cancer

  9/20/2017

• XBiotech Announces Presentation Of Phase II Study Data Evaluating Mabp1 For The Treatment Of Hidradenitis Suppurativa

  9/7/2017

• XBiotech Plunged 66% After Discontinuing Phase III Colorectal Cancer Study

  6/12/2017

• XBiotech Presents Phase III Findings For Its Antibody Therapy For Colorectal Cancer At The 2017 ASCO Meeting

  6/1/2017

• XBiotech Sinks To A New Low After The EMA Rejects Lead Drug

  5/19/2017

• Struggling XBiotech Quietly Discloses Exec Resignation

  5/15/2017

• XBiotech To Provide First Quarter 2017 Business Update

  4/28/2017

• XBiotech Craters After Disappointing EMA Meeting

  4/21/2017

• XBiotech Announces Additions To Its Scientific Advisory Board

  4/10/2017

• XBiotech Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections

  4/4/2017

• XBiotech Reports Affirmative Interim Analysis Of Global Phase III Colorectal Cancer Study

  2/27/2017